<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01452659</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-385/CCT-001</org_study_id>
    <secondary_id>U1111-1123-6815</secondary_id>
    <secondary_id>JapicCTI-111590</secondary_id>
    <nct_id>NCT01452659</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids</brief_title>
  <official_title>A Phase II, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of TAK-385 10, 20, and 40 mg (p.o.) in the Treatment of Uterine Fibroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of TAK-385, once daily
      (QD), for 12 weeks in women with uterine fibroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase II, multicenter, randomized, double-blind, parallel-group,
      placebo-controlled for evaluation of the efficacy and safety of TAK-385 10, 20, and 40 mg
      (p.o.) following once daily administration for 12 weeks in women with uterine fibroids.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in menstrual blood loss</measure>
    <time_frame>Week 12 (one menstrual cycle)</time_frame>
    <description>Blood loss will be assessed using the Pictorial Blood Loss Assessment Chart (PBAC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in menstrual blood loss</measure>
    <time_frame>Up to Week 6</time_frame>
    <description>Blood loss will be assessed using PBAC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in menstrual blood loss</measure>
    <time_frame>Up to Week 12.</time_frame>
    <description>Blood loss will be assessed using PBAC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amenorrhea</measure>
    <time_frame>Week 12 (one menstrual cycle).</time_frame>
    <description>Amenorrhea will be assessed using PBAC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amenorrhea</measure>
    <time_frame>Up to Week 6.</time_frame>
    <description>Amenorrhea will be assessed using PBAC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amenorrhea</measure>
    <time_frame>Up to Week 12.</time_frame>
    <description>Amenorrhea will be assessed using PBAC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in menstrual blood loss</measure>
    <time_frame>Week 12 (one menstrual cycle)</time_frame>
    <description>Change in menstrual blood loss measured by PBAC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myoma Volume</measure>
    <time_frame>Up to Week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine Volume</measure>
    <time_frame>Up to Week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Concentration in Blood</measure>
    <time_frame>Up to Week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Symptom</measure>
    <time_frame>Up to Week 12.</time_frame>
    <description>Measured by Numerical Rating Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Clinical Symptoms</measure>
    <time_frame>Up to Week 12.</time_frame>
    <description>Assessed by clinical laboratory tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) Score</measure>
    <time_frame>Up to Week 12.</time_frame>
    <description>QOL will be assessed using Uterine Fibroid Symptom and Quality of Life (UFS-QOL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density</measure>
    <time_frame>Up to Week 12.</time_frame>
    <description>Measured by Dual-energy X-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent Adverse Events</measure>
    <time_frame>Up to Week 16.</time_frame>
    <description>Treatment-emergent adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through the last visit (Week 16)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Up to Week 12.</time_frame>
    <description>Vital signs will include body temperature, sitting blood pressure, and pulse (bpm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight</measure>
    <time_frame>Up to Week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiograms</measure>
    <description>Up to Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum NTx</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>NTx is one of the biochemical bone metabolism markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum BAP</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>BAP is one of the biochemical bone metabolism markers</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>TAK-385 10 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-385 20 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-385 40 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-385</intervention_name>
    <description>TAK-385 10 mg, tablets, orally, once daily for up to 12 weeks.</description>
    <arm_group_label>TAK-385 10 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-385</intervention_name>
    <description>TAK-385 20 mg, tablets, orally, once daily for up to 12 weeks.</description>
    <arm_group_label>TAK-385 20 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-385</intervention_name>
    <description>TAK-385 40 mg, tablets, orally, once daily for up to 12 weeks.</description>
    <arm_group_label>TAK-385 40 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>TAK-385 placebo-matching tablets, orally, once daily for up to 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The participant has been diagnosed with uterine fibroids and has never received
             surgical treatment for the myoma.

          2. The participant is a premenopausal woman.

          3. The participant has one or more measurable noncalcified myomas confirmed by
             transvaginal sonography.

          4. The participant has experienced regular menstrual cycles

          5. The participant is diagnosed as menorrhagia

        Exclusion Criteria:

          1. Participants with a screening Hb &lt;8 g/dL

          2. Participants with a previous or current history of blood disorders

          3. Participants with a known history of severe hypersensitivity or severe allergy to
             sanitary goods

          4. Participants with lower abdominal pain due to irritable bowel syndrome or severe
             interstitial cystitis

          5. Participants with a previous or current history of thyroid dysfunction

          6. Participants with a previous or current history of pelvic inflammatory disease

          7. Participants with a positive PAP smear test result

          8. Participants with a history of panhysterectomy or bilateral oophorectomy

          9. Participants judged by investigator to have marked abnormal uterine bleeding or
             anovulatory bleeding

         10. Participants with a previous or current history of a malignant tumor

         11. Participants who have been treated with any of the following drugs: anticoagulant
             drug, antiplatelet drug, tranexamic acid, selective estrogen receptor modulator
             (SERM), activated vitamin D, other vitamin D, calcitonin, ipriflavone, steroid
             hormone, vitamin K, teriparatide, or denosumab

         12. Participants who have been treated with any of the following drugs: oral contraceptive
             and sex hormone preparation, gonadotropin-releasing hormone (GnRH) analogue,
             dienogest, danazol, or aromatase inhibitor

         13. Participants who have been treated with a bisphosphonate preparation

         14. Participants with a previous or current history of severe hypersensitivity or severe
             allergy to drugs

         15. Participants with non-diagnosable abnormal genital bleeding

         16. Participants with a previous or current history of osteoporosis, bone mass loss, or
             other metabolic bone diseases

         17. Participants with clinically significant cardiovascular disease or uncontrollable
             hypertension

         18. Participants judged by investigator to be inappropriate to participate in this study
             based on the 12-lead electrocardiogram (ECG) findings

         19. Participants with active liver disease or jaundice, or with alanine aminotransferase
             (ALT), aspartate aminotransferase (AST), or total bilirubin &gt; 1.5 times the upper
             limit of normal (ULN)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chiba-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Itchihara-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsuno-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsuyama-shi</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nihama-shi</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukui-shi</city>
        <state>Fukui</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iizuka-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yanagigawa-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mebashi-shi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ebetsu-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amagasaki-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kamakura-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oita-shi</city>
        <state>Oita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ibaraki-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sakai-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tondabayashi-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suginami-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyama-shi</city>
        <state>Toyama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2011</study_first_submitted>
  <study_first_submitted_qc>October 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2011</study_first_posted>
  <last_update_submitted>January 17, 2013</last_update_submitted>
  <last_update_submitted_qc>January 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

